Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus

Gian Domenico Sebastiani; Mauro Galeazzi; Angela Tincani; Jean Charles Piette; Josep Font; Flavio Allegri; Alessandro Mathieu; Josef Smolen; Enrique De Ramon Garrido; Antonio Fernandez-Nebro; Anna Jedryka-Goral; Chryssa Papasteriades; Gabriella Morozzi; Francesca Bellisai; Ornella De Pita; Roberto Marcolongo

Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus

Gian Domenico Sebastiani, Mauro Galeazzi, Angela Tincani, Jean Charles Piette, Josep Font, Flavio Allegri, Alessandro Mathieu, Josef Smolen, Enrique De Ramon Garrido, Antonio Fernandez-Nebro, Anna Jedryka-Goral, Chryssa Papasteriades, Gabriella Morozzi, Francesca Bellisai, Ornella De Pita, Roberto Marcolongo

Istituto Dermopatico dell'Immacolata , IDI

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To test the prevalences and the clinical associations of anticardiolipin (aCL) and anti-β₂GPI (aβ₂GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). Methods: 574 SLE patients from 7 European countries were tested for aCL and aβ₂GPI by ELISA methods. Results: aCL of IgG, IgM, and IgA isotypes were detected in 22.8%, 14%, and 13.9% of the patients, respectively. IgG and IgM aβ₂GPI were detected in 20% of the patients. The presence of aCL was highly associated with the presence of aβ₂GPI. Medium-high titer IgG aCL and aβ₂GPI were associated with thrombosis, with similar sensitivity, specificity, and positive predictive value. When present at medium-high titer, IgG aCL were associated with thrombocytopenia, IgM aCL with hemolytic anemia, and cerebrovascular accidents, IgA aCL with livedo reticularis and Raynaud's phenomenon. Conclusions: aCL, when present at medium-high titer, are as important as aβ₂GPI, as a risk factor for thrombosis. Medium-high titer aCL, but not aβ₂GPI, are associated with other clinical features of the antiphospholipid syndrome.

Original language	English
Pages (from-to)	344-351
Number of pages	8
Journal	Scandinavian Journal of Rheumatology
Volume	28
Issue number	6
Publication status	Published - 1999

Keywords

aβGPI
aCL
Antiphospholipid syndrome
Systemic lupus erythematosus

ASJC Scopus subject areas

Immunology
Rheumatology

Access to Document

Fingerprint Dive into the research topics of 'Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this

Sebastiani, G. D., Galeazzi, M., Tincani, A., Piette, J. C., Font, J., Allegri, F., Mathieu, A., Smolen, J., De Ramon Garrido, E., Fernandez-Nebro, A., Jedryka-Goral, A., Papasteriades, C., Morozzi, G., Bellisai, F., De Pita, O., & Marcolongo, R. (1999). Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 28(6), 344-351.

Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. / Sebastiani, Gian Domenico; Galeazzi, Mauro; Tincani, Angela; Piette, Jean Charles; Font, Josep; Allegri, Flavio; Mathieu, Alessandro; Smolen, Josef; De Ramon Garrido, Enrique; Fernandez-Nebro, Antonio; Jedryka-Goral, Anna; Papasteriades, Chryssa; Morozzi, Gabriella; Bellisai, Francesca; De Pita, Ornella; Marcolongo, Roberto.

In: Scandinavian Journal of Rheumatology, Vol. 28, No. 6, 1999, p. 344-351.

Research output: Contribution to journal › Article › peer-review

Sebastiani, GD, Galeazzi, M, Tincani, A, Piette, JC, Font, J, Allegri, F, Mathieu, A, Smolen, J, De Ramon Garrido, E, Fernandez-Nebro, A, Jedryka-Goral, A, Papasteriades, C, Morozzi, G, Bellisai, F, De Pita, O & Marcolongo, R 1999, 'Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus', Scandinavian Journal of Rheumatology, vol. 28, no. 6, pp. 344-351.

Sebastiani, Gian Domenico ; Galeazzi, Mauro ; Tincani, Angela ; Piette, Jean Charles ; Font, Josep ; Allegri, Flavio ; Mathieu, Alessandro ; Smolen, Josef ; De Ramon Garrido, Enrique ; Fernandez-Nebro, Antonio ; Jedryka-Goral, Anna ; Papasteriades, Chryssa ; Morozzi, Gabriella ; Bellisai, Francesca ; De Pita, Ornella ; Marcolongo, Roberto. / Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. In: Scandinavian Journal of Rheumatology. 1999 ; Vol. 28, No. 6. pp. 344-351.

@article{58b5119a5ecf4a84a15d2c41b5e9988b,

title = "Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus",

abstract = "Objective: To test the prevalences and the clinical associations of anticardiolipin (aCL) and anti-β2GPI (aβ2GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). Methods: 574 SLE patients from 7 European countries were tested for aCL and aβ2GPI by ELISA methods. Results: aCL of IgG, IgM, and IgA isotypes were detected in 22.8%, 14%, and 13.9% of the patients, respectively. IgG and IgM aβ2GPI were detected in 20% of the patients. The presence of aCL was highly associated with the presence of aβ2GPI. Medium-high titer IgG aCL and aβ2GPI were associated with thrombosis, with similar sensitivity, specificity, and positive predictive value. When present at medium-high titer, IgG aCL were associated with thrombocytopenia, IgM aCL with hemolytic anemia, and cerebrovascular accidents, IgA aCL with livedo reticularis and Raynaud's phenomenon. Conclusions: aCL, when present at medium-high titer, are as important as aβ2GPI, as a risk factor for thrombosis. Medium-high titer aCL, but not aβ2GPI, are associated with other clinical features of the antiphospholipid syndrome.",

keywords = "aβGPI, aCL, Antiphospholipid syndrome, Systemic lupus erythematosus",

author = "Sebastiani, {Gian Domenico} and Mauro Galeazzi and Angela Tincani and Piette, {Jean Charles} and Josep Font and Flavio Allegri and Alessandro Mathieu and Josef Smolen and {De Ramon Garrido}, Enrique and Antonio Fernandez-Nebro and Anna Jedryka-Goral and Chryssa Papasteriades and Gabriella Morozzi and Francesca Bellisai and {De Pita}, Ornella and Roberto Marcolongo",

year = "1999",

language = "English",

volume = "28",

pages = "344--351",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus

AU - Sebastiani, Gian Domenico

AU - Galeazzi, Mauro

AU - Tincani, Angela

AU - Piette, Jean Charles

AU - Font, Josep

AU - Allegri, Flavio

AU - Mathieu, Alessandro

AU - Smolen, Josef

AU - De Ramon Garrido, Enrique

AU - Fernandez-Nebro, Antonio

AU - Jedryka-Goral, Anna

AU - Papasteriades, Chryssa

AU - Morozzi, Gabriella

AU - Bellisai, Francesca

AU - De Pita, Ornella

AU - Marcolongo, Roberto

PY - 1999

Y1 - 1999

N2 - Objective: To test the prevalences and the clinical associations of anticardiolipin (aCL) and anti-β2GPI (aβ2GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). Methods: 574 SLE patients from 7 European countries were tested for aCL and aβ2GPI by ELISA methods. Results: aCL of IgG, IgM, and IgA isotypes were detected in 22.8%, 14%, and 13.9% of the patients, respectively. IgG and IgM aβ2GPI were detected in 20% of the patients. The presence of aCL was highly associated with the presence of aβ2GPI. Medium-high titer IgG aCL and aβ2GPI were associated with thrombosis, with similar sensitivity, specificity, and positive predictive value. When present at medium-high titer, IgG aCL were associated with thrombocytopenia, IgM aCL with hemolytic anemia, and cerebrovascular accidents, IgA aCL with livedo reticularis and Raynaud's phenomenon. Conclusions: aCL, when present at medium-high titer, are as important as aβ2GPI, as a risk factor for thrombosis. Medium-high titer aCL, but not aβ2GPI, are associated with other clinical features of the antiphospholipid syndrome.

AB - Objective: To test the prevalences and the clinical associations of anticardiolipin (aCL) and anti-β2GPI (aβ2GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). Methods: 574 SLE patients from 7 European countries were tested for aCL and aβ2GPI by ELISA methods. Results: aCL of IgG, IgM, and IgA isotypes were detected in 22.8%, 14%, and 13.9% of the patients, respectively. IgG and IgM aβ2GPI were detected in 20% of the patients. The presence of aCL was highly associated with the presence of aβ2GPI. Medium-high titer IgG aCL and aβ2GPI were associated with thrombosis, with similar sensitivity, specificity, and positive predictive value. When present at medium-high titer, IgG aCL were associated with thrombocytopenia, IgM aCL with hemolytic anemia, and cerebrovascular accidents, IgA aCL with livedo reticularis and Raynaud's phenomenon. Conclusions: aCL, when present at medium-high titer, are as important as aβ2GPI, as a risk factor for thrombosis. Medium-high titer aCL, but not aβ2GPI, are associated with other clinical features of the antiphospholipid syndrome.

KW - aβGPI

KW - aCL

KW - Antiphospholipid syndrome

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0033256156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033256156&partnerID=8YFLogxK

M3 - Article

C2 - 10665739

AN - SCOPUS:0033256156

VL - 28

SP - 344

EP - 351

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 6

ER -